A Nobel Laureate's Biotech Just Ran Out of Road

The company had never sold a product. Its total revenue from licensing and collaboration deals in 2025 was just $11.2 million, a rounding error against its losses. As of the end of 2025, the accumulated deficit had ballooned to $596.5 million.

In April 2025, Caribou tried to buy time. It cut 32% of its workforce and narrowed its pipeline, projecting that the savings would stretch its runway into the second half of 2027. But stretching a runway and actually taking off are two very different things. By October 2026, the company admitted it had failed to secure the financing needed for later-stage trials.

The remaining 87 employees in Berkeley received layoff notices, with departures expected by December 7.

CRISPR's Winter Won't End

Caribu isn't dying alone. The entire CRISPR sector has been stuck in something that looks less like a rough patch and more like a prolonged ice age.

Consider the body count from 2025 alone. Intellia Therapeutics slashed 27% of its workforce and killed a rare-disease program. Prime Medicine replaced its CEO, laid off 25% of staff, and dramatically narrowed its focus. Scribe Therapeutics cut nearly 20% of its team. Spotlight Therapeutics shut down entirely after disappointing preclinical results. Even Editas Medicine and Sangamo Therapeutics have been shrinking and restructuring.

The pattern is clear: investors have lost patience with platform-heavy companies that need huge amounts of follow-on capital. The first CRISPR-based therapy (Casgevy, for sickle cell disease) was approved in late 2023, proving the technology works in humans. But approval of one product didn't translate into a funding bonanza for the broader field. If anything, it sharpened investor scrutiny. They want near-term, credible paths to revenue, not sprawling pipelines that might pay off in a decade.

Then there's the safety overhang. Intellia paused two late-stage trials in late 2025 after a liver-safety signal, and the FDA placed those studies on clinical hold. That kind of event doesn't just hurt one company; it spooks investors across the entire sector.

The Paradox of Transformative Science

This is the part that stings. CRISPR is real. It works. Caribou's own data showed its off-the-shelf CAR-T cells could produce responses comparable to the custom-made versions that cost hundreds of thousands of dollars per patient. Vispa-cel's 12-month progression-free survival of 51% in the confirmatory group was competitive with approved autologous therapies.

But "competitive" isn't enough when you're a small biotech asking investors for hundreds of millions more dollars to run pivotal trials in a market that has collectively decided gene editing is too risky, too expensive, and too far from profitability. It's like having a restaurant with incredible food but no way to pay rent. The quality of the meal doesn't matter if you can't keep the lights on.

Caribu was founded in 2011 by Doudna, Rachel Haurwitz, Martin Jinek, and James Berger to commercialize CRISPR discoveries from the Doudna lab at UC Berkeley. It was, in many ways, the OG CRISPR company. Its intellectual property even formed the foundation for other companies; Intellia, for example, licensed IP from Caribou.

What Happens Now

Caribu says it's evaluating "strategic alternatives," which in biotech-speak means: we're hoping someone buys us, acquires our assets, or merges with us before the money runs out completely. A small team will stay on to manage this process.

The question is whether anyone wants to buy what Caribou is selling. The company has clinical data, CRISPR IP, and manufacturing know-how. For a larger pharma company with deeper pockets and an existing cell-therapy infrastructure, those assets could be a bargain. Fire sales in biotech often produce the best deals for acquirers.

But for the employees, the patients enrolled in trials, and the broader CRISPR community, this is a loss. Not because the science failed, but because the market decided the science wasn't worth funding right now.

Somewhere in that gap between "this technology could change medicine" and "this company can't raise another round" lies one of biotech's oldest and cruelest truths: being right isn't the same as surviving long enough to prove it.

$103M to Fix the Gene That's Slowly Destroying 1 in 1,000 Kidneys

A new biotech just emerged from stealth with $103 million to attempt something nobody has done: fix the broken genes behind the most common inherited kidney disease. The science comes from Yale, the money comes from RA Capital, and the stakes couldn't be higher.